{"id":"shr-a1811-injection-pertuzumab-injection","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Diarrhea"},{"rate":"15-25","effect":"Nausea"},{"rate":"15-20","effect":"Fatigue"},{"rate":"10-15","effect":"Vomiting"},{"rate":"5-10","effect":"Rash"},{"rate":"5-10","effect":"Left ventricular dysfunction"},{"rate":"5-15","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Pertuzumab targets the extracellular domain II of HER2, preventing ligand-induced heterodimerization of HER2 with HER3 and other HER family members. This dual mechanism—direct HER2 blockade combined with prevention of HER2-HER3 signaling—leads to reduced phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathway activation, resulting in cell cycle arrest and apoptosis in HER2-overexpressing tumors.","oneSentence":"Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, inhibiting tumor cell growth signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:32.407Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy)"},{"name":"HER2-positive early breast cancer (neoadjuvant and adjuvant settings)"}]},"trialDetails":[{"nctId":"NCT06057610","phase":"PHASE3","title":"A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-10-16","conditions":"HER2-PositiveRecurrent or Metastatic Breast Cancer","enrollment":868},{"nctId":"NCT07196774","phase":"PHASE3","title":"A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-10-23","conditions":"Early-stage or Locally Advanced HER2-positive Breast Cancer","enrollment":740},{"nctId":"NCT05353361","phase":"PHASE2","title":"A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-05-23","conditions":"Breast Cancer","enrollment":402}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SHR-A1811 Injection ； Pertuzumab Injection","genericName":"SHR-A1811 Injection ； Pertuzumab Injection","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, inhibiting tumor cell growth signaling. Used for HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy), HER2-positive early breast cancer (neoadjuvant and adjuvant settings).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}